NanoString Technologies Inc. Announces National Cancer Institute Has Adopted Its Gene Expression Technology

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc., a privately held life sciences company marketing a molecular barcoding detection system, today announced that the National Cancer Institute (NCI) is employing its nCounter™ Analysis System at two of its core labs. One system was purchased by the NCI Center for Cancer Research (CCR) through the Institute’s Office of Science and Technology Partnerships, and a second was purchased by SAIC-Frederick, operations and technical support contractor to NCI-Frederick.

Back to news